S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
$10.99
$10.92
$10.36
$11.40
$171.48M-0.0139,747 shs4,382 shs
Mexco Energy Co. stock logo
MXC
Mexco Energy
$12.77
-17.0%
$10.87
$9.02
$16.52
$26.79M0.697,744 shs28,047 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$8.25
-1.3%
$10.17
$7.72
$27.48
$1.11B0.411.05 million shs772,457 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.13
$0.00
$0.12
$0.25
$128.47M15.28 million shs1.65 million shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
-0.05%0.00%-0.18%+1.57%+4.87%
Mexco Energy Co. stock logo
MXC
Mexco Energy
-18.66%-1.88%+22.79%+24.59%+2.57%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-1.32%-9.24%-22.75%-15.73%-67.00%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%+1.67%-12.53%-33.73%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Mexco Energy Co. stock logo
MXC
Mexco Energy
N/AN/AN/AN/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.5385 of 5 stars
3.33.00.00.01.13.31.3
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
3.00
Buy$12.5013.74% Upside
Mexco Energy Co. stock logo
MXC
Mexco Energy
N/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.57
Moderate Buy$34.38316.67% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/A

Current Analyst Ratings

Latest ZOM, VIR, MXC, and EVE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2024
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$13.50 ➝ $12.50
3/15/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
2/23/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$9.00 ➝ $10.00
2/14/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $110.00
1/29/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$23.00 ➝ $9.00
1/23/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $85.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/AN/AN/AN/AN/AN/A
Mexco Energy Co. stock logo
MXC
Mexco Energy
$7.01M3.82$2.39 per share5.35$7.86 per share1.62
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$39.49M28.10N/AN/A$11.82 per share0.70
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M5.10N/AN/A$0.24 per share0.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Mexco Energy Co. stock logo
MXC
Mexco Energy
$4.66M$0.9014.19N/A28.37%11.61%10.91%6/24/2024 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$615.06M-$4.59N/AN/AN/A-713.69%-34.92%-27.73%5/2/2024 (Confirmed)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.04N/AN/A-137.10%-8.13%-7.68%5/9/2024 (Estimated)

Latest ZOM, VIR, MXC, and EVE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.99N/A+$0.99N/AN/AN/A  
4/1/2024Q4 2023
Zomedica Corp. stock logo
ZOM
Zomedica
N/A-$0.01-$0.01N/A$7.00 million$7.34 million    
2/22/2024Q4 2023
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$1.14-$0.86+$0.28-$0.86$11.18 million$16.80 million    
2/9/2024Q3 2024
Mexco Energy Co. stock logo
MXC
Mexco Energy
N/A$0.16+$0.16$0.16N/A$1.66 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/AN/AN/AN/AN/A
Mexco Energy Co. stock logo
MXC
Mexco Energy
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/AN/AN/A
Mexco Energy Co. stock logo
MXC
Mexco Energy
N/A
17.85
17.85
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
9.05
9.05
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
11.06
10.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/A
Mexco Energy Co. stock logo
MXC
Mexco Energy
5.89%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
2.90%
Mexco Energy Co. stock logo
MXC
Mexco Energy
51.02%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
18.10%
Zomedica Corp. stock logo
ZOM
Zomedica
4.18%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
EVe Mobility Acquisition Corp stock logo
EVE
EVe Mobility Acquisition
N/A15.60 million15.15 millionNot Optionable
Mexco Energy Co. stock logo
MXC
Mexco Energy
32.10 million1.03 millionNot Optionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
587134.50 million110.16 millionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
85979.95 million938.99 millionNot Optionable

ZOM, VIR, MXC, and EVE Headlines

SourceHeadline
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
accesswire.com - April 9 at 6:30 AM
Zomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call TranscriptZomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcript
msn.com - April 2 at 4:06 PM
Q4 2023 Zomedica Corp Earnings CallQ4 2023 Zomedica Corp Earnings Call
finance.yahoo.com - April 2 at 8:30 AM
ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023
investorplace.com - April 1 at 9:06 PM
Zomedica reports Q4 resultsZomedica reports Q4 results
msn.com - April 1 at 5:27 PM
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in LiquidityZomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
accesswire.com - April 1 at 4:05 PM
The Next Millionaire-Makers: 3 Penny Stocks With Massive Upside PotentialThe Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potential
investorplace.com - April 1 at 3:12 PM
Zomedica to Report Fourth Quarter and Full Year 20…Zomedica to Report Fourth Quarter and Full Year 20…
pharmiweb.com - March 20 at 9:17 AM
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
accesswire.com - March 20 at 6:30 AM
Zomedica Pharmaceuticals Corp (ZOM)Zomedica Pharmaceuticals Corp (ZOM)
investing.com - March 15 at 7:52 AM
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) PlatformZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
accesswire.com - March 14 at 6:30 AM
Zomedica Provides NYSE American Listing UpdateZomedica Provides NYSE American Listing Update
accesswire.com - March 13 at 4:45 PM
Sidoti & Company, LLC: Sidoti Events, LLCs Virtual March Small-Cap ConferenceSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conference
finanznachrichten.de - March 12 at 11:26 AM
Zomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary ConferencesZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
finanznachrichten.de - March 12 at 8:22 AM
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary ConferencesZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
accesswire.com - March 12 at 6:30 AM
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working DogsZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
accesswire.com - March 7 at 6:30 AM
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
accesswire.com - March 5 at 6:30 AM
Zomedica Pharmaceuticals Corp. (ZOM)Zomedica Pharmaceuticals Corp. (ZOM)
uk.finance.yahoo.com - March 1 at 2:46 PM
Zomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health ConferencesZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
finanznachrichten.de - February 8 at 9:14 AM
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health ConferencesZomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
finance.yahoo.com - February 8 at 9:14 AM
Zomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share ConsolidationZomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation
finanznachrichten.de - February 6 at 5:00 PM
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)
finance.yahoo.com - February 6 at 5:00 PM
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ETZomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET
finance.yahoo.com - February 6 at 7:00 AM
Zomedica Corp. (ZOM) Interactive Stock Chart - Yahoo FinanceZomedica Corp. (ZOM) Interactive Stock Chart - Yahoo Finance
finance.yahoo.com - February 4 at 8:05 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

EVe Mobility Acquisition logo

EVe Mobility Acquisition

NYSE:EVE
EVe Mobility Acquisition Corp does not have significant operations. The company focuses on effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on the automotive and mobility industry. The company was incorporated in 2021 and is based in Wilmington, Delaware.
Mexco Energy logo

Mexco Energy

NYSE:MXC
Mexco Energy Corporation, an independent oil and gas company, engages in the acquisition, exploration, development, and production of natural gas, crude oil, condensate, and natural gas liquids in the United States. It owns partial interests in approximately 6,400 gross producing wells located in the states of Texas, New Mexico, Oklahoma, Louisiana, Alabama, Mississippi, Arkansas, Wyoming, Kansas, Colorado, Montana, Virginia, North Dakota, and Ohio. It also owned leasehold mineral, royalty, and other interests in approximately 2,768 net acres. The company was formerly known as Miller Oil Company and changed its name to Mexco Energy Corporation in April 1980. Mexco Energy Corporation was incorporated in 1972 and is based in Midland, Texas.
Vir Biotechnology logo

Vir Biotechnology

NASDAQ:VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Zomedica logo

Zomedica

NYSEAMERICAN:ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.